A detailed history of Parallel Advisors, LLC transactions in Mirum Pharmaceuticals, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 440 shares of MIRM stock, worth $19,580. This represents 0.0% of its overall portfolio holdings.

Number of Shares
440
Previous 416 5.77%
Holding current value
$19,580
Previous $14,000 21.43%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$33.68 - $44.74 $808 - $1,073
24 Added 5.77%
440 $17,000
Q4 2023

Feb 09, 2024

SELL
$27.14 - $34.93 $542 - $698
-20 Reduced 4.59%
416 $12,000
Q1 2023

May 20, 2024

BUY
$19.19 - $24.1 $383 - $482
20 Added 4.81%
436 $10,000
Q1 2023

Apr 25, 2023

BUY
$19.19 - $24.1 $690 - $867
36 Added 9.0%
436 $10,000
Q4 2021

Jan 20, 2022

SELL
$13.05 - $19.35 $7,216 - $10,700
-553 Reduced 58.03%
400 $6,000
Q2 2021

Aug 06, 2021

BUY
$15.84 - $20.6 $8,759 - $11,391
553 Added 138.25%
953 $16,000
Q4 2019

Jan 30, 2020

BUY
$6.84 - $25.9 $2,736 - $10,360
400 New
400 $10,000

Others Institutions Holding MIRM

About Mirum Pharmaceuticals, Inc.


  • Ticker MIRM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,751,700
  • Market Cap $1.64B
  • Description
  • Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...
More about MIRM
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.